| No. pts. | Median (range) | |||
| Before prostatectomy | PSA (ng/ml) | 16 | 8.4 (4.2 - 18) | |
| 3 + 3 | 4 | |||
| 3 + 4 | 6 | |||
| Gleason score | 4 + 3 | 2 | ||
| 4 + 4 | 2 | |||
| 4 + 5 | 2 | |||
| T1c | 8 | |||
| Clinical stage | T2a | 6 | ||
| T2b | 2 | |||
| Low | 2 | |||
| Risk group (D’Amico) | Intermediate | 10 | ||
| High | 4 | |||
| Before HIFU | PSA (ng/ml) | 16 | 0.98 (0.318 - 3.2) | |
| 3 + 3 | 2 | |||
| 3 + 4 | 8 | |||
| Gleason score | 4 + 3 | 3 | ||
| 4 + 4 | 1 | |||
| 5 + 4 | 2 | |||
| pT2a | 3 | |||
| Pathological stage | pT2b | 9 | ||
| pT3a | 3 | |||
| pT3b | 1 | |||
| Risk group (after prostatectomy) | Intermediate | 10 | ||
| High | 6 |